Apoptotic Pharmacogenetic Index (API) of Hlavaty et al for Infliximab Therapy in Crohn's Disease

Description

Hlavaty et al used the Apoptotic Pharmacogenetic Index (API) to predict response to infliximab therapy by a patient with Crohn's disease. The components of the API are associated with the apoptotic response of immune cells to infliximab therapy. The authors are from University Hospital Gasthuisberg in Leuven, Belgium, and University Hospital Bratislava in Slovakia.

Polymorphisms included:

(1) Fas ligand at 843

(2) Fas at 670

(3) Caspase9 at 93

Parameter	Polymorphism	Points
Fas ligand 843	TT	0
	CT	1
	CC	1
Fas 670	GG	0
	AG	1
	AA	1
Caspase9 93	TT	0
	CT	0
	CC	1

apoptotic pharmacogenetic index =

= SUM(points for all 3 ligands)

Interpretation:

• minimum API: 0

• maximum API: 3

• The higher the API the greater the improvement for a patient with Crohn's disease following the first infusion of infliximab.

To read more or access our algorithms and calculators, please log in or register.

Description

Specialty

ICD-10